Bloomfield Hills internal medicine physician Amjad Rass was excited to reunite with family in Syria last month for the first ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Eli Lilly(NYSE: LLY) sells a broad variety of drugs across treatment ... four businesses and its solid history of dividend ...